BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

JSJ Pharmaceuticals, Inc. Named One of Charleston's Top Ten Innovators of the Year


7/17/2007 9:47:41 AM

CHARLESTON, S.C., July 17 /PRNewswire/ -- JSJ Pharmaceuticals, Inc. (JSJ) is pleased to announce that it has been selected by the Charleston Regional Business Journal as one of this year's top ten innovators in the Charleston region. Among the noted innovations, JSJ has just completed the introduction of the patented PharmaDur(TM) bioadhesive technology, which has been introduced in the Umecta PD(TM) (urea 40%) and Aclaro PD(TM) (hydroquinone USP 4%) product lines.

The PharmaDur(TM) bioadhesive delivery system creates an invisible, breathable matrix providing a controlled release of medication to the applied areas. This represents an important technical advancement for the Umecta(R) and Aclaro(R) brands. Due to the controlled release of the active ingredients, PharmaDur(TM) has been shown to reduce the potential for irritation while improving the hydration of the skin. In addition to the Umecta PD(TM) and Aclaro PD(TM) brands, JSJ is working to introduce additional pharmaceutical actives utilizing the PharmaDur(TM) bioadhesive delivery technology.

"The introduction of Umecta PD(TM) and Aclaro PD(TM) is a significant breakthrough for JSJ and recognition of this innovation by the business community is a real honor," states Jonathan Alba, JSJ's Chief Operating Officer. "JSJ looks forward to additional product introductions utilizing the PharmaDur(TM) technology and the improvement it will provide to future topical drug development."

The PharmaDur(TM) technology has been made available in the following presentations:

Umecta PD(TM) (urea 40%) Emulsion -- 5oz. NDC 68712-017-03 -- 7oz. NDC 68712-017-02 Umecta PD(TM) (urea 40%) Topical Suspension -- 9oz. NDC 68712-018-02 Aclaro PD(TM) (hydroquinone 4% USP) Emulsion -- 1.5oz. NDC 68712-015-02

About JSJ Pharmaceuticals, Inc.

JSJ Pharmaceuticals, Inc. is a specialty pharmaceutical company that identifies and brings to market pharmaceutical products targeted for topical use primarily in the dermatology community. JSJ aims to be the "Next Generation" in skin-related pharmaceuticals, providing clinicians with a "toolbox" for the management of daily challenges faced in their clinical practice. To learn more, go to http://www.jsjpharm.com

Media Contact: Jon Knowles 843.965.8333 ext 104 jknowles@jsjpharm.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

JSJ Pharmaceuticals, Inc.

CONTACT: Jon Knowles of JSJ Pharmaceuticals, Inc., +1-843-965-8333 ext104, jknowles@jsjpharm.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES